Cyclophosphamide for scleroderma interstitial lung disease. Tashkin DP, Elashoff R, Clements PJ et al.: Cyclophosphamide versus placebo in scleroderma lung disease. N. Engl. J. Med. (2006) 354(25):2655-2666.

Autor: Antoniu SA; Clinic of Pulmonary Disease, 30 Dr I Cihac Street, 700115 Iasi, Romania. sabinaantoniu@excite.com

Publikováno v: Expert opinion on investigational drugs [Expert Opin Investig Drugs] 2007 Mar; Vol. 16 (3), pp. 393-5.

Disease Features and Gastrointestinal Microbial Composition in Patients with Systemic Sclerosis from Two Independent Cohorts.

Autor: Andréasson K; Lund University, Sweden., Lee SM; Semel Institute for Neuroscience, University of California Los Angeles, Los Angeles, California., Lagishetty V; David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California., Wu M; David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California., Howlett N; Stanford University, Palo Alto, California., English J; Boston Medical Center, Boston, Massachusetts., Hesselstrand R; Lund University, Sweden., Clements PJ; David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California., Jacobs JP; David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California.; Veterans Administration Greater Los Angeles Healthcare System, Los Angeles, California., Volkmann ER; David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California.

Publikováno v: ACR open rheumatology [ACR Open Rheumatol] 2022 May; Vol. 4 (5), pp. 417-425. Date of Electronic Publication: 2022 Feb 17.

Predictive Significance of Serum Interferon-Inducible Protein Score for Response to Treatment in Systemic Sclerosis-Related Interstitial Lung Disease.

Autor: Assassi S; University of Texas Health Science Center at Houston., Li N; University of California, Los Angeles., Volkmann ER; University of California, Los Angeles., Mayes MD; University of Texas Health Science Center at Houston., Rünger D; University of California, Los Angeles., Ying J; University of Texas Health Science Center at Houston., Roth MD; University of California, Los Angeles., Hinchcliff M; Yale University, New Haven, Connecticut., Khanna D; University of Michigan, Ann Arbor., Frech T; University of Utah, Salt Lake City., Clements PJ; University of California, Los Angeles., Furst DE; University of California, Los Angeles., Goldin J; University of California, Los Angeles., Bernstein EJ; Columbia University, New York, New York., Castelino FV; Massachusetts General Hospital and Harvard University, Boston, Massachusetts., Domsic RT; University of Pittsburgh, Pittsburgh, Pennsylvania., Gordon JK; Hospital for Special Surgery, New York, New York., Hant FN; Medical University of South Carolina, Charleston., Shah AA; Johns Hopkins University School of Medicine, Baltimore, Maryland., Shanmugam VK; George Washington University, Washington, DC., Steen VD; Georgetown University, Washington, DC., Elashoff RM, Tashkin DP; University of California, Los Angeles.

Publikováno v: Arthritis & rheumatology (Hoboken, N.J.) [Arthritis Rheumatol] 2021 Jun; Vol. 73 (6), pp. 1005-1013. Date of Electronic Publication: 2021 Apr 20.

The renoprotective efficacy and safety of genetically-engineered human bone marrow-derived mesenchymal stromal cells expressing anti-fibrotic cargo.

Autor: Li, Yifang^1,2 (AUTHOR), Hunter, Alex^1,2 (AUTHOR), Wakeel, Miqdad M.^1,2 (AUTHOR), Sun, Guizhi^3,4 (AUTHOR), Lau, Ricky W. K.^2,3 (AUTHOR), Broughton, Brad R. S.^1,2 (AUTHOR), Pino, Ivan E. Oyarce^1,2 (AUTHOR), Deng, Zihao⁵ (AUTHOR), Zhang, Tingfang^2,3 (AUTHOR), Murthi, Padma^1,2 (AUTHOR), Del Borgo, Mark P.^1,2 (AUTHOR), Widdop, Robert E.^1,2 (AUTHOR), Polo, Jose M.^3,4,6,7 (AUTHOR), Ricardo, Sharon D.^2,3 (AUTHOR) sharon.ricardo@monash.edu, Samuel, Chrishan S.^1,2,3,8 (AUTHOR) chrishan.samuel@monash.edu

Publikováno v: Stem Cell Research & Therapy. 11/19/2024, Vol. 15 Issue 1, p1-27. 27p.

Expert agreement on EULAR/EUSTAR recommendations for the management of systemic sclerosis

Autor: Walker, Kyle M., Pope, Janet, Alkassab, F, Molitor, Ja, Shapiro, Ls, Fessler, Bj, Gran, Jt, Goldberg, A, Medsger, TA Jr, VALENTINI, Gabriele, Csuka, Me, Griffing, L, Herrick, A, Connolly, M, Vacca, A, Riemekasten, G, Wigley, Fm, Farge, D, Johnson, Sr, Matucci Cerinic, M, Czirjak, L, Toloza, Sm, Mahmud, Th, Frech, Tm, Voskuyl, Ae, Merkel, Pa, Domsic, R, Emery, P, Steen, V, Rudnicka, L, Denton, Cp, Clements, Pj, Chatterjee, S, Kahaleh, B, Hayat, S, Mouthon, L, Lafyatis, R, Lally, Ev, Krieg, T, Chung, L, Catoggio, Lj, Mayes, Md, Anderson, Me, Silver, R, Proudman, S, Seibold, Jr, Senécal, Jl, Stevens, W, Hachulla, E, Inanc, M, Wollheim, F, Distler, O, Katsumoto, Tr, Hsu, V, Collier, Dh, Furst, D, Mckown, K, Khanna, D, Volkov, S, Mathieu, A, Baron, M, Kaminska, Ea, Khalidi, Na, Hudson, M, Markland, J, Masetto, A, Docherty, P.

Objective. The European League Against Rheumatism/EULAR Scleroderma Trials and Research group (EULAR/EUSTAR) has published recommendations for the management of systemic sclerosis (SSc). Members of the Scleroderma Clinical Trials Consortium and the C

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______3977::7e3e0ecd510d258b9ca842d9464b2f1c
http://hdl.handle.net/11591/370048